Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.

Telix Pharmaceuticals Ltd ( ASX: TLX) shares are catching the eye on Tuesday. In morning trade, the radiopharmaceuticals company's shares are up 14% to $11.62.

The government has approved a new update of the list of free and reimbursed medicines, one of the most extensive in recent years. According to the announcement made by the Minister of Health, ...

Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...

The FDA has given tentative approval to the abbreviated new drug application (ANDA) for PNT2003, a radioequivalent version of lutetium Lu 177 dotatate (Lutathera) indicated for treatment of ...

The therapy shrunk tumors in 46 percent of patients in a Phase I trial and showed strong PSA responses at the recommended dose.

Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver ...

Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.

As part of the 2025 Ontario budget, the Indigenous Opportunities Financing Program (IOFP) program was tripled to $3 billion ...

The $250 million investment comes through the Indigenous Opportunities Financing Program, and administered through the Building Ontario Fund. The provincial guarantee is the largest of its kind since ...

Eckert & Ziegler SE and Molecular Partners AG have entered into a partnership to develop and potentially manufacture DARPin-based radiopharmaceutical therapies for cancer treatment. Eckert & Ziegler ...